- Home
- HY vs ETNB Comparison
HY vs ETNB Comparison
Compare HY & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HY
- ETNB
- Stock Information
- Founded
- HY 1991
- ETNB 2018
- Country
- HY United States
- ETNB United States
- Employees
- HY N/A
- ETNB N/A
- Industry
- HY Construction/Ag Equipment/Trucks
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- HY Industrials
- ETNB Health Care
- Exchange
- HY Nasdaq
- ETNB Nasdaq
- Market Cap
- HY 933.9M
- ETNB 864.2M
- IPO Year
- HY N/A
- ETNB 2019
- Fundamental
- Price
- HY $53.88
- ETNB $6.31
- Analyst Decision
- HY Strong Buy
- ETNB Buy
- Analyst Count
- HY 2
- ETNB 7
- Target Price
- HY $80.00
- ETNB $30.33
- AVG Volume (30 Days)
- HY 91.3K
- ETNB 1.3M
- Earning Date
- HY 02-25-2025
- ETNB 02-27-2025
- Dividend Yield
- HY 2.55%
- ETNB N/A
- EPS Growth
- HY 41.25
- ETNB N/A
- EPS
- HY 8.90
- ETNB N/A
- Revenue
- HY $4,267,899,999.00
- ETNB N/A
- Revenue This Year
- HY $6.62
- ETNB N/A
- Revenue Next Year
- HY N/A
- ETNB N/A
- P/E Ratio
- HY $6.05
- ETNB N/A
- Revenue Growth
- HY 4.70
- ETNB N/A
- 52 Week Low
- HY $48.73
- ETNB $5.99
- 52 Week High
- HY $84.44
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- HY 57.99
- ETNB 31.27
- Support Level
- HY $48.84
- ETNB $5.99
- Resistance Level
- HY $51.85
- ETNB $6.65
- Average True Range (ATR)
- HY 1.53
- ETNB 0.40
- MACD
- HY 0.63
- ETNB -0.14
- Stochastic Oscillator
- HY 89.30
- ETNB 15.70
About HY Hyster-Yale Materials Handling Inc.
Hyster-Yale Materials Handling Inc designs, engineers, manufactures, sells, and services a line of lift trucks and aftermarket parts. It manufactures components, such as frames, masts, and transmissions; and assembles lift trucks and the products are market under the Hyster and Yale brand names to independent Hyster and Yale retail dealerships. The company operates through three geographical regions namely: the Americas, EMEA, JAPIC, of which Americas accounts for the larger share of the revenue.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).